Invetx Inc., a pioneer in protein-based therapeutics for animal health, announces that it has agreed to be acquired by Dechra Pharmaceuticals Limited (Dechra), a global specialist veterinary pharmaceuticals business, for up to $520 million in total consideration on a cash-free and debt-free basis. “We are thrilled to be joining forces with Dechra Pharmaceuticals, a global leader in animal health. Our pipeline of monoclonal antibody therapeutics for chronic, serious diseases in cats and dogs is highly complementary to Dechra’s broad portfolio of speciality therapeutics for companion animals and accelerates Dechra’s differentiated position in the veterinary health industry,” said Juergen Horn, Dr.med.vet., Ph.D., chief executive officer and co-founder, Invetx.
Read the full article: Invetx Announces Upcoming Acquisition by Dechra Pharmaceuticals, Global Leader in Animal Health //
Source: https://www.businesswire.com/news/home/20240718774207/en/Invetx-Announces-Upcoming-Acquisition-by-Dechra-Pharmaceuticals-Global-Leader-in-Animal-Health